Mechanism of action of venetoclax (ABT-199) and its side effects
Treatment at first relapse in multiple myeloma: how to choose a drug?
Achieving deep responses in previously treated CLL patients
COMy 2017: Day 2 discussion on relapsed myeloma, treatment, plasma cell leukemia and awards
Arnon Nagler et al.
Venetoclax and the future of treatment of multiple myeloma